Man Who Had Three Covid Jabs Has High Antibody Levels

"); jQuery("#212 h3").html("

"); jQuery(document).ready(function() { jwplayer.key='EKOtdBrvhiKxeOU807UIF56TaHWapYjKnFiG7ipl3gw='; var playerInstance = jwplayer("jquery_jwplayer_1"); playerInstance.setup({ file: "https://newsstatic.rthk.hk/audios/mfile_1593135_1_20210528174914.mp3", skin: { url: location.href.split('/', 4).join('/') + '/jwplayer/skin/rthk/five.css', name: 'five' }, hlshtml: true, width: "100%", height: 30, wmode: 'transparent', primary: navigator.userAgent.indexOf("Trident")>-1 ? "flash" : "html5", events: { onPlay: function(event) { dcsMultiTrack('DCS.dcsuri', 'https://news.rthk.hk/rthk/en/component/k2/1593135-20210528.mp3', 'WT.ti', ' Audio at newsfeed', 'WT.cg_n', '#rthknews', 'WT.cg_s', 'Multimedia','WT.es','https://news.rthk.hk/rthk/en/component/k2/1593135-20210528.htm', 'DCS.dcsqry', '' ); } } }); }); });
2021-05-28 HKT 16:50
Professor Ivan Hung speaks to RTHK's Wendy Wong
A Hong Kong man who received three doses of coronavirus vaccine has a very high antibody level against Covid-19, medical experts said on Friday.
However, they added that they can't determine whether or not this positive discovery is down to him receiving a shot of Sinovac on top of his two BioNTech jabs.
The 32-year-old man first had a dose of BioNTech in March. But his second dose was delayed when vaccinations with the German-made jab were temporarily halted due to packaging defects.
When he couldn't get the BioNTech jab as planned, the man decided to go for a Sinovac one instead.
Then, when use of BioNTech resumed in Hong Kong, he took a second dose of this one as well.
Professor Ivan Hung from the University of Hong Kong said antibody levels vary among vaccinated people as their immune systems react differently.
He said although tests showed the man has an antibody level four times higher than average, some people who only receive two shots of BioNTech can also reach that level.
“That could be the result of two doses of BioNTech or it could be the result of three doses of Covid-19 vaccine. Unfortunately, we did not have the antibody level after the second dose, so we cannot draw any conclusion just by looking at the antibody level,” he said.
“If you compare to the highest level of the subjects who received two doses of BioNTech, it is comparable.”
Hung said people who have received two doses of coronavius vaccine, produced by either BioNTech or Sinovac, will have adequate antibodies and they should last for nine months to a year.
He said people do not need a third dose of vaccine, but will probably require a booster jab next year.
HSBC Fined HK$4.2M Over Disclosure Breaches In Research Reports
The Securities and Futures Commission (SFC) has reprimanded and imposed a fine of HK$4.2 million on HSBC for breaching ... Read more
Philippines: The Hidden Fintech Gem You Cant Afford To Miss | Lito Villanueva
The Philippines is the fastest-growing digital economy and home to one of Southeast Asia’s most valuable fintech unic... Read more
SBI And Chainlink Partner On Blockchain And Digital Asset Use
SBI Group, one of Japan’s largest financial conglomerates with assets exceeding the equivalent of US$200 billion, has... Read more
China Considers Yuan-Backed Stablecoins To Advance Global Currency Push
China is considering permitting the use of yuan-backed stablecoins for the first time in a move that could support wide... Read more
Financial Sanctions: LSEG Risk Intelligence Answers Your Key Questions
Financial sanctions are essential government tools for achieving foreign policy objectives – and compliance is mandat... Read more
Korea Development Bank Leads $45M Bridge Round For Upstage
South Korea’s Upstage has secured a US$45 million Series B bridge round supported by Korea Development Bank (KDB), Am... Read more